Show simple item record

dc.contributor.authorSibley, Kathryn
dc.contributor.authorStern, Peter L
dc.contributor.authorKnowles, Margaret A
dc.date.accessioned2009-11-10T10:31:38Z
dc.date.available2009-11-10T10:31:38Z
dc.date.issued2001-07-19
dc.identifier.citationFrequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. 2001, 20 (32):4416-8 Oncogeneen
dc.identifier.issn0950-9232
dc.identifier.pmid11466624
dc.identifier.urihttp://hdl.handle.net/10541/85761
dc.description.abstractMutations in FGFR3 have been identified in several tumour types including bladder carcinoma, cervical carcinoma, and multiple myeloma. In bladder carcinoma, we recently identified FGFR3 mutations in 41% of tumours, making this the most frequently mutated putative oncogene identified in bladder cancer to date. We have now investigated the frequency of FGFR3 mutation in a panel of 125 tumours and 13 cell lines from various other organs. We analysed the mutation hotspots in exons 7, 10 and 15 by direct DNA sequencing, and found one mutation in exon 7 (S249C) in 1/28 (3.5%) cervical tumours. Mutations were not detected in stomach, rectum, colon, prostate, ovarian, breast, brain, or renal tumours, nor were they found in any of the cell lines included in this study. We conclude that FGFR3 is commonly mutated in bladder carcinoma and only rarely in cervical carcinoma. Several tumour types appear not to possess any mutations in FGFR3, suggesting that these mutations are important only in the development of certain types of tumour.
dc.language.isoenen
dc.subjectCancer DNAen
dc.subjectCanceren
dc.subjectCultured Tumour Cellsen
dc.subjectUrinary Bladder Canceren
dc.subjectUterine Cervical Canceren
dc.subject.meshCarcinoma
dc.subject.meshDNA, Neoplasm
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMutation
dc.subject.meshNeoplasms
dc.subject.meshProtein-Tyrosine Kinases
dc.subject.meshReceptor, Fibroblast Growth Factor, Type 3
dc.subject.meshReceptors, Fibroblast Growth Factor
dc.subject.meshTumor Cells, Cultured
dc.subject.meshUrinary Bladder Neoplasms
dc.subject.meshUterine Cervical Neoplasms
dc.titleFrequency of fibroblast growth factor receptor 3 mutations in sporadic tumours.en
dc.typeArticleen
dc.contributor.departmentICRF Clinical Centre, St. James's University Hospital, Leeds, LS9 7TF, UK.en
dc.identifier.journalOncogeneen
html.description.abstractMutations in FGFR3 have been identified in several tumour types including bladder carcinoma, cervical carcinoma, and multiple myeloma. In bladder carcinoma, we recently identified FGFR3 mutations in 41% of tumours, making this the most frequently mutated putative oncogene identified in bladder cancer to date. We have now investigated the frequency of FGFR3 mutation in a panel of 125 tumours and 13 cell lines from various other organs. We analysed the mutation hotspots in exons 7, 10 and 15 by direct DNA sequencing, and found one mutation in exon 7 (S249C) in 1/28 (3.5%) cervical tumours. Mutations were not detected in stomach, rectum, colon, prostate, ovarian, breast, brain, or renal tumours, nor were they found in any of the cell lines included in this study. We conclude that FGFR3 is commonly mutated in bladder carcinoma and only rarely in cervical carcinoma. Several tumour types appear not to possess any mutations in FGFR3, suggesting that these mutations are important only in the development of certain types of tumour.


This item appears in the following Collection(s)

Show simple item record